Tumor suppressing role of serum-derived exosomal microRNA-15a in osteosarcoma cells through the GATA binding protein 2/murine double minute 2 axis and the p53 signaling pathway

References

• Huang F, Zhou P, Wang Z, et al. Knockdown of TBRG4 suppresses proliferation, invasion and promotes apoptosis of osteosarcoma cells by downregulating TGF-beta1 expression and PI3K/AKT signaling pathway. Arch Biochem Biophys. 2020;686:108351.
   PubMed Web of Science ®Google Scholar
• Anwar MA, El-Baba C, Elnaggar MH, et al. Novel therapeutic strategies for spinal osteosarcomas. Semin Cancer Biol. 2020;64:83–92.
   PubMed Web of Science ®Google Scholar
• Abarrategi A, Tornin J, Martinez-Cruzado L, et al. Osteosarcoma: cells-of-Origin, cancer stem cells, and targeted therapies. Stem Cells Int. 2016;2016:3631764.
   PubMed Web of Science ®Google Scholar
• Kebudi R, Ozger H, Kizilocak H, et al. Osteosarcoma after hematopoietic stem cell transplantation in children and adolescents: case report and review of the literature. Pediatr Blood Cancer. 2016;63(9):1664–1666.
   PubMed Web of Science ®Google Scholar
• Zhang H, Lin J, Chen J, et al. DDX11-AS1 contributes to osteosarcoma progression via stabilizing DDX11. Life Sci. 2020;254:117392.
   PubMed Web of Science ®Google Scholar
• Harrandah AM, Mora RA, Chan EKL. Emerging microRNAs in cancer diagnosis, progression, and immune surveillance. Cancer Lett. 2018;438:126–132.
   PubMed Web of Science ®Google Scholar
• Palmini G, Marini F, Brandi ML. What is new in the miRNA world regarding osteosarcoma and chondrosarcoma? Molecules. 2017;22(3):417.
   Web of Science ®Google Scholar
• Wang J, Liu S, Shi J, et al. The Role of miRNA in the Diagnosis, Prognosis, and Treatment of Osteosarcoma. Cancer Biother Radiopharm. 2019;34(10):605–613.
   PubMed Web of Science ®Google Scholar
• Huang E, Liu R, Chu Y. miRNA-15a/16: as tumor suppressors and more. Future Oncol. 2015;11(16):2351–2363.
   PubMed Web of Science ®Google Scholar
• Cai CK, Zhao GY, Tian LY, et al. miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep. 2012;28(5):1764–1770.
   PubMed Web of Science ®Google Scholar
• Maminezhad H, Ghanadian S, Pakravan K, et al. A panel of six-circulating miRNA signature in serum and its potential diagnostic value in colorectal cancer. Life Sci. 2020;258:118226.
   PubMed Web of Science ®Google Scholar
• Tu C, He J, Chen R, et al. The emerging role of exosomal non-coding RNAs in musculoskeletal diseases. Curr Pharm Des. 2019;25(42):4523–4535.
   PubMed Web of Science ®Google Scholar
• Zhou X, Hao Q, Lu H. Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol. 2019;11(4):293–305.
   PubMed Web of Science ®Google Scholar
• Lazo PA. Reverting p53 activation after recovery of cellular stress to resume with cell cycle progression. Cell Signal. 2017;33:49–58.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, et al. The role of GATA2 in lethal prostate cancer aggressiveness. Nat Rev Urol. 2017;14(1):38–48.
   PubMed Web of Science ®Google Scholar
• Shimizu R, Yamamoto M. Quantitative and qualitative impairments in GATA2 and myeloid neoplasms. IUBMB Life. 2020;72(1):142–150.
   PubMed Web of Science ®Google Scholar
• Song SH, Jeon MS, Nam JW, et al. Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer. Oncogene. 2018;37(8):993–1004.
   PubMed Web of Science ®Google Scholar
• Han Q, Xu X, Li J, et al. GATA4 is highly expressed in childhood acute lymphoblastic leukemia, promotes cell proliferation and inhibits apoptosis by activating BCL2 and MDM2. Mol Med Rep. 2017;16(5):6290–6298.
   PubMed Web of Science ®Google Scholar
• Skalniak L, Twarda-Clapa A, Neochoritis CG, et al. A fluorinated indole-based MDM 2 antagonist selectively inhibits the growth of p53 wtosteosarcoma cells. FEBS J. 2019;286(7):1360–1374.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140.
   PubMed Web of Science ®Google Scholar
• Qin F, Tang H, Zhang Y, et al. Bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-208a promotes osteosarcoma cell proliferation, migration, and invasion. J Cell Physiol. 2020;235(5):4734–4745.
   PubMed Web of Science ®Google Scholar
• Zhao W, Qin P, Zhang D, et al. Long non-coding RNA PVT1 encapsulated in bone marrow mesenchymal stem cell-derived exosomes promotes osteosarcoma growth and metastasis by stabilizing ERG and sponging miR-183-5p. Aging (Albany NY). 2019;11(21):9581–9596.
   PubMedGoogle Scholar
• Fu J, Rodova M, Roy SK, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 2013;330(1):22–32.
   PubMed Web of Science ®Google Scholar
• Collantes M, Martinez-Velez N, Zalacain M, et al. Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [(18)F]FDG and sodium [(18)F]fluoride PET. BMC Cancer. 2018;18(1):1193.
   PubMedGoogle Scholar
• Zhang H, Wang J, Ren T, et al. Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B. Cancer Lett. 2020;490:54–65.
   PubMed Web of Science ®Google Scholar
• Zhao M, Zhang RZ, Qi DW, et al. CacyBP/SIP promotes tumor progression by regulating apoptosis and arresting the cell cycle in osteosarcoma. Exp Ther Med. 2020;20(2):1397–1404.
   PubMed Web of Science ®Google Scholar
• Jin XM, Xu B, Zhang Y, et al. LncRNA SND1-IT1 accelerates the proliferation and migration of osteosarcoma via sponging miRNA-665 to upregulate POU2F1. Eur Rev Med Pharmacol Sci. 2019;23:9772–9780.
   PubMed Web of Science ®Google Scholar
• Galardi A, Colletti M, Di Paolo V, et al. Exosomal miRNAs in pediatric cancers. Int J Mol Sci. 2019;20(18):4600.
   Web of Science ®Google Scholar
• Zhou X, Fan Y, Ye W, et al. Identification of the novel target genes for osteosarcoma therapy based on comprehensive bioinformatic analysis. DNA Cell Biol. 2020;39(7):1172–1180.
   PubMed Web of Science ®Google Scholar
• Shi J, Fu Q, Yang P, et al. Downregulation of microRNA-15a-3p is correlated with clinical outcome and negatively regulates cancer proliferation and migration in human osteosarcoma. J Cell Biochem. 2018;119(1):1215–1222.
   PubMed Web of Science ®Google Scholar
• Liu T, Xu Z, Ou D, et al. The miR-15a/16 gene cluster in human cancer: a systematic review. J Cell Physiol. 2019;234(5):5496–5506.
   PubMed Web of Science ®Google Scholar
• Tian X, Zhang J, Yan L, et al. MiRNA-15a inhibits proliferation, migration and invasion by targeting TNFAIP1 in human osteosarcoma cells. Int J Clin Exp Pathol. 2015;8:6442–6449.
   PubMed Web of Science ®Google Scholar
• Lin ZP, Zhu YL, Ratner ES. Targeting cyclin-dependent kinases for treatment of gynecologic cancers. Front Oncol. 2018;8:303.
   PubMed Web of Science ®Google Scholar
• Wang S, Ma F, Feng Y, et al. Role of exosomal miR21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (Review). Int J Oncol. 2020;56:1055–1063.
   PubMed Web of Science ®Google Scholar
• Cuscino N, Raimondi L, De Luca A, et al. Gathering novel circulating exosomal microrna in osteosarcoma cell lines and possible implications for the disease. Cancers (Basel). 2019;11(12):1924.
   PubMed Web of Science ®Google Scholar
• Ran JJ, Li Y, Liu L, et al. Apelin enhances biological functions in lung cancer A549 cells by downregulating exosomal miR-15a-5p. Carcinogenesis. 2020;42(2):243-253.
   PubMed Web of Science ®Google Scholar
• Robinson JL, Tzou KS, Parker AS, et al. GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer. Br J Radiol. 2017;90(1075):20170174.
   PubMed Web of Science ®Google Scholar
• Kumar MS, Hancock DC, Molina-Arcas M, et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell. 2012;149(3):642–655.
   PubMed Web of Science ®Google Scholar
• Liao G, Yang D, Ma L, et al. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy. Eur J Med Chem. 2018;159:1–9.
   PubMed Web of Science ®Google Scholar
• Gupta A, Shah K, Oza MJ, et al. Reactivation of p53 gene by MDM2 inhibitors: a novel therapy for cancer treatment. Biomed Pharmacother. 2019;109:484–492.
   PubMed Web of Science ®Google Scholar
• Rusiecki R, Witkowski J, Joanna JA. MDM2-p53 interaction inhibitors: the current state-of-art and updated patent review (2010-present). Recent Pat Anticancer Drug Discov. 2019;14(4):324–369.
   PubMed Web of Science ®Google Scholar